PMID- 25934147
OWN - NLM
STAT- MEDLINE
DCOM- 20160704
LR  - 20181202
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 18
IP  - 10
DP  - 2015
TI  - A network meta-analysis to compare simeprevir with boceprevir and telaprevir in 
      combination with peginterferon-alpha and ribavirin in patients infected with genotype 
      1 Hepatitis C virus.
PG  - 787-96
LID - 10.3111/13696998.2015.1046880 [doi]
AB  - OBJECTIVE: To conduct a network meta-analysis (NMA) to assess the relative 
      efficacy and safety of simeprevir, a second generation oral protease inhibitor 
      (PI), compared to telaprevir and boceprevir in combination with pegylated 
      interferon-alpha and ribavirin (PR) in patients with chronic hepatitis C. METHODS: A 
      systematic literature review and NMA of randomized controlled trials involving 
      anti-virals added to PR were conducted. Electronic database searches and hand 
      searches were conducted to identify relevant publications. Outcomes of interest 
      included sustained virologic response (SVR), incidence of adverse events (AEs), 
      and discontinuation due to AEs. Networks were based on treatment-, dose-, and 
      duration-specific nodes. Sub-group analyses were conducted to investigate 
      heterogeneity, based on Metavir scores, sub-genotypes 1a/1b, and prior response. 
      RESULTS: A total of 15 publications were considered for the base case of the 
      meta-analysis. Simeprevir was associated with higher SVR rates than PR alone. 
      Compared to telaprevir and boceprevir, SVR rates tended to be higher for 
      simeprevir, with odds ratios ranging from 1.27 [0.81-2.00] to 2.61 [1.44-4.74] in 
      treatment-naive and from 1.04 [0.78-1.38] to 1.74 [0.84-3.61] in 
      treatment-experienced patients, respectively. In terms of safety, the risks of 
      anemia and discontinuations due to AEs were lower for simeprevir compared to PR 
      alone, telaprevir, and boceprevir. The risk of rash was lower for simeprevir 
      compared to telaprevir, and similar compared to PR alone and boceprevir. 
      CONCLUSION: This NMA in genotype 1 HCV patients suggests a similar or better 
      efficacy and tolerability profile for simeprevir compared to telaprevir and 
      boceprevir.
FAU - Taieb, Vanessa
AU  - Taieb V
AD  - a a Amaris , London , UK.
FAU - Pacou, Maud
AU  - Pacou M
AD  - b b Amaris , Paris , France.
FAU - Ho, Sophia
AU  - Ho S
AD  - a a Amaris , London , UK.
FAU - Pettre, Segolene
AU  - Pettre S
AD  - a a Amaris , London , UK.
FAU - Van Sanden, Suzy
AU  - Van Sanden S
AD  - c c Janssen EMEA , Beerse , Belgium.
FAU - Pisini, Marta
AU  - Pisini M
AD  - c c Janssen EMEA , Beerse , Belgium.
FAU - Ustianowski, Andrew
AU  - Ustianowski A
AD  - d d North Manchester General Hospital , Manchester , UK.
FAU - Mehnert, Angelika
AU  - Mehnert A
AD  - e e Janssen-Cilag GmbH , Neuss , Germany.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20150526
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
RN  - 0 (Antiviral Agents)
RN  - 0 (Immunologic Factors)
RN  - 0 (Interferon-alpha)
RN  - 0 (Oligopeptides)
RN  - 0 (Protease Inhibitors)
RN  - 49717AWG6K (Ribavirin)
RN  - 655M5O3W0U (telaprevir)
RN  - 89BT58KELH 
      (N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide)
RN  - 9DLQ4CIU6V (Proline)
RN  - 9WS5RD66HZ (Simeprevir)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Databases, Bibliographic
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - Hepacivirus/*drug effects/genetics/immunology
MH  - Hepatitis C, Chronic/*drug therapy/genetics
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - Interferon-alpha/therapeutic use
MH  - Oligopeptides/therapeutic use
MH  - Proline/analogs & derivatives/therapeutic use
MH  - Protease Inhibitors/*therapeutic use
MH  - Ribavirin/therapeutic use
MH  - Simeprevir/therapeutic use
MH  - Viral Load/drug effects
OTO - NOTNLM
OT  - Genotype 1
OT  - Hepatitis C virus
OT  - Network meta-analysis
OT  - Protease inhibitors
OT  - Simeprevir
OT  - Treatment
EDAT- 2015/05/03 06:00
MHDA- 2016/07/05 06:00
CRDT- 2015/05/03 06:00
PHST- 2015/05/03 06:00 [entrez]
PHST- 2015/05/03 06:00 [pubmed]
PHST- 2016/07/05 06:00 [medline]
AID - 10.3111/13696998.2015.1046880 [doi]
PST - ppublish
SO  - J Med Econ. 2015;18(10):787-96. doi: 10.3111/13696998.2015.1046880. Epub 2015 May 
      26.